Haywire T Cells Attack Protein In "Bad" Cholesterol
La Jolla Institute for ImmunologyDetecting these T cells may lead to diagnostics to better detect heart disease—and disease severity.
Detecting these T cells may lead to diagnostics to better detect heart disease—and disease severity.
To treat and prevent these diseases, researchers need to understand why a lack of oxygen would affect the immune system.
When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
Researchers at La Jolla Institute for Immunology (LJI) have found that Zika virus can mutate to become more infective—and potentially break through pre-existing immunity.
Ebola virus polymerase hijacks a cellular protein called GSPT1. An experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells.
Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson's disease have a clear "genetic signature" of the disease in their memory T cells. The scientists hope that targeting these genes may open the door to new Parkinson's treatments and diagnostics.
The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.
Researchers at La Jolla Institute for Immunology (LJI) have discovered new genes in CD4+ "helper" T cell subset that are linked to risk of autoimmune diseases. As they work to shed light on the exact functions of these CD4+ T cell subsets, the researchers have uncovered major differences between donors based on genetics and how the cells may function in men and women.
The Conrad Prebys Foundation has given more than $1.17 million to support La Jolla Institute for Immunology's (LJI) Flow Cytometry Core and more than $415,000 to fuel infectious disease research led by LJI Instructor Julie Burel, Ph.D.
Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.
Scientists at La Jolla Institute for Immunology (LJI) have found they can dramatically improve survival of mice with cystic fibrosis through a partial bone marrow transplant. Their new study in the Journal of Immunology shows that a partial bone marrow transplant helps these mice by introducing a population of healthy immune cells called monocytes.
La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement. The agreement marks another milestone in one of the most enduring industry-academic collaborations in the world.
An artery is not like a nose. Or is it? Scientists at La Jolla Institute for Immunology (LJI) have discovered that immune cells in arteries can "sniff" out their surroundings and cause inflammation.
Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system respond to SARS-CoV-2, the virus that causes COVID-19.
Scientists at the La Jolla Institute for Immunology (LJI) have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.
A long, long time ago, the BCG vaccine was approved for use against tuberculosis (TB), and it's still given to infants today. For generations, the vaccine has saved lives and prevented untold suffering.
Scientists at La Jolla Institute for Immunology (LJI) and Massachusetts Institute of Technology (MIT), have found a possible way to improve the effectiveness of COVID-19 vaccines—and any vaccine.
About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes. Although there are effective treatments for psoriasis, not everyone responds to these therapies—and for many, the relief is temporary.
New research shows how genetic variations linked to severe cases of COVID-19 affect our immune cells. The study is one of the first in-depth look at the connections between COVID-19 severity and gene expression in many types of immune cells. This work could guide the development of new COVID-19 therapies to boost immune cell function.
Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates. The new research will guide the development of more effective COVID-19 antibody therapies and help scientists develop effective vaccines to address emerging viral variants.
Regulatory T cells (Tregs) help control inflammation and autoimmunity in the body. Unfortunately, it has proven difficult to find the right molecular ingredients to induce stable iTregs. A new study reports that Vitamin C and TET proteins can work together to give Tregs their life-saving power.
In a new Nature Immunology study, researchers at La Jolla Institute for Immunology (LJI) report that T cells can be engineered to clear tumors without succumbing to T cell exhaustion.
Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.
Researchers at La Jolla Institute for Immunology (LJI) have shed light on a process in immune cells that may explain why some people develop cardiovascular diseases. Their research, published recently in Genome Biology, shows the key role that TET enzymes play in keeping immune cells on a healthy track as they mature. The scientists found that other enzymes do play a role in this process—but TET enzymes do the heavy lifting.
New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients do not respond to anti-PD-1 cancer immunotherapies—also called checkpoint inhibitors. The team reports that these patients may have tumors with high numbers of T follicular regulatory (Tfr) cells.
The National Cancer Institute (NCI) of the National Institutes of Health has granted over $4.2 million to launch the Cancer Epitope Database and Analysis Resource (CEDAR), led by La Jolla Institute for Immunology (LJI) Professors Alessandro Sette, Dr. Biol. Sci., and Bjoern Peters, Ph.D.
The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI will be led by Professor Sujan Shresta, Ph.D., a member of the Institute’s Center for Infectious Disease and Vaccine Research.
In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
Viruses churn out genetic material in parts of the cell where it's not supposed to be. Cancer cells do too. A new study shows that a tumor-suppressor enzyme called DAPK3 is an essential component of a multi-protein system that senses misplaced genetic material in tumor cells, and slows tumor growth by activating the fierce-sounding STING pathway.
Erica Ollmann Saphire, Ph.D., has been appointed President and CEO of La Jolla Institute for Immunology (LJI), the Institute announced today. Dr. Saphire will become La Jolla Institute’s fifth president when she formally begins her term on September 1, 2021. She will succeed current LJI President Mitchell Kronenberg, who has successfully led the organization for the past 18 years.
Translational research led by scientists at La Jolla Institute for Immunology (LJI) has resulted in a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes.
La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates.
A new study led by scientists at La Jolla Institute for Immunology (LJI) suggests that T cells try to fight SARS-CoV-2 by targeting a broad range of sites on the virus—beyond the key sites on the virus's spike protein. By attacking the virus from many angles, the body has the tools to potentially recognize different SARS-CoV-2 variants.
A big question on people's minds these days: how long does immunity to SARS-CoV-2 last following infection? Now a research team from La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton has uncovered an interesting clue. Their new study suggests that people with severe COVID-19 cases may be left with more of the protective "memory" T cells needed to fight reinfection.
The findings, based on analyses of blood samples from 188 COVID-19 patients, suggest that responses to the novel coronavirus, SARS-CoV-2, from all major players in the "adaptive" immune system, which learns to fight specific pathogens, can last for at least eight months after the onset of symptoms from the initial infection.
The COVID-19 pandemic has highlighted how our small genetic differences can have a tremendous effect on how our bodies respond to disease. Researchers have created 3D maps of how enhancer sequences and genes interact in several types of immune cells. Their new study opens the door to understanding individual risk for diseases from asthma to cancer.
Researchers at La Jolla Institute for Immunology (LJI) have found that people with sepsis have never-before-seen particles in their blood. The scientists are the first to show that these particles, called elongated neutrophil-derived structures (ENDS), break off of immune cells and change their shape as they course through the body.
While quick-acting inhalers and medications can reduce inflammation during an asthma attack, people with asthma have few tools to prevent the next attack from coming. Now researchers at La Jolla Institute for Immunology (LJI) have discovered that blocking two immune molecules at the same time is key to preventing asthma attacks in a mouse model.
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system's T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies.
It's long been thought that having "autoreactive" T cells in the pancreas was a sure sign of type 1 diabetes. Yet a new study led by scientists at La Jolla Institute for Immunology (LJI) shows that even healthy people have these cells lurking in the pancreas—in surprisingly high numbers.
A new international study led by scientists at La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton is the first to give a detailed snapshot of how the body's CD4+ T cells respond to the SARS-CoV-2 virus. Among the findings, their work suggests that early in the illness, patients hospitalized with severe cases of COVID-19 develop a novel T cell subset that can potentially kill B cells and reduce antibody production.
In a new study, researchers at La Jolla Institute for Immunology (LJI) report that a protein called TL1A drives fibrosis in several mouse models, triggering tissue remodeling, and making it harder for lungs and airways to function normally.
A multi-layered, virus-specific immune response is important for controlling SARS-CoV-2 during the acute phase of the infection and reducing COVID-19 disease severity, with the bulk of the evidence pointing to a much bigger role for T cells than antibodies.
Scientists at the La Jolla Institute for Immunology (LJI) have received $3.5 million as part of a team award from Aligning Science Across Parkinson’s (ASAP) to support a three-year study into how immune cells may contribute to Parkinson's disease.
In a new Immunity study, researchers at La Jolla Institute for Immunology (LJI) show that one way to improve the body's immune response to vaccines is to factor in antigen valency. Valency refers to the number of antibody binding sites on an antigen.
Blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes.
Scientists at La Jolla Institute for Immunology (LJI) have tracked down the rare stem cells that generate neutrophils in human bone marrow. This research, published August 18, 2020, in Immunity, gives researchers a potential path for intervening in diseases where neutrophil development goes awry.
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows that memory helper T cells that recognize common cold coronaviruses also recognize matching sites on SARS-CoV-2, the virus that causes COVID-19.
At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place. In a new study, LJI scientists show that certain T lymphocytes, a type of white blood cell, that start out trying to fight the disease can end up increasing inflammation and making atherosclerosis cases even worse.